HES1 and ductal breast carcinoma in situ: Immunohistochemical analysis of 150 primary breast cancer specimens revealed weak nuclear expression of Hes1 in 5 cases of ductal carcinoma in situ (DCIS), while its expression was significantly upregulated in 53 cases of invasive ductal carcinoma (IDC) (35.3%) (83).